DMX-200 for Focal Segmental Glomerulosclerosis
This trial is investigating whether a drug called DMX-200 can help treat patients with a kidney disease called FSGS.
- Focal Segmental Glomerulosclerosis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are new patients being taken in for this clinical trial right now?
"That is correct, the online information from clinicaltrials.gov affirms that this trial is still looking for participants. The posting date was May 30th, 2022, and it was last updated on July 21st of the same year. They are expecting to have 286 patients total from 18 different hospitals or clinics."
How many people are being given the opportunity to participate in this trial?
"To conduct this study, we need 286 participants who meet the pre-specified inclusion criteria. These individuals can enroll at one of many clinical sites such as ACTION3 Investigational Site 4 in Phoenix, Arizona or ACTION3 Investigational site 10 located in Northridge, California."
What are the potential side effects of DMX-200?
"DMX-200 has been found to be safe in multiple rounds of testing and has some efficacy data, so it received a score of 3."
Does this experiment only accept people below a certain age?
"Eligibility for this clinical trial is restricted to individuals that are aged 18-80. If you are under 18 or over 65, there 1 and 4 trials you might be eligible for respectively."
If I meet the qualifications, may I sign up for this research project?
"This study is looking for 286 participants aged 18-80 who have FSGS. The following criteria must also be met: · Patients must be 18 to 80 years old · If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, or sodium-glucose co-transporter-2 (SGLT2) inhibitors, the dose and regimen must be stable for ≥12 weeks prior to Screening · Urine PCR >1.5 g/g (>169.5 mg/mmol) or 24-hour total protein >1.5 g"
Are the research sites for this trial widely dispersed geographically?
"To make travelling for this trial as easy as possible on participants, the team has set up 18 enrolment sites. You can find these in Phoenix, Northridge, Baltimore and other cities."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- ACTION 3 Investigator Site 19: < 48 hours
Average response time
- < 2 Days